ReviewNeuro-oncology2016
Is there a role for early chemotherapy in the management of pituitary adenomas?
Review in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Management of Recurrent and Aggressive Non-Functioning Pituitary Adenomas.Journal of clinical medicine · 2025Review
- The periphery of pituitary macroadenoma expressed higher invasive capability: the importance of clinical implication.Discover oncology · 2025Article
- Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.The Journal of clinical endocrinology and metabolism · 2023Article
- Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson's disease.Frontiers in immunology · 2023Article
- Aggressive pituitary tumours and pituitary carcinomas.Nature reviews. Endocrinology · 2021Review
- Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section.Acta neurochirurgica · 2021Review
- Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions.Reviews in endocrine & metabolic disorders · 2020Review
- Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?Endocrinology and metabolism (Seoul, Korea) · 2020Review
- Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough?Journal of the Endocrine Society · 2019Article
- Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series.Neuro-oncology practice · 2018Article
- Identification of Novel Genes Involved in the Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature Review.Frontiers in oncology · 2018Article
- Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions.Frontiers in endocrinology · 2018Review
- How effective is temozolomide for treating pituitary tumours and when should it be used?Pituitary · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Pituitary adenomas are benign intracranial neoplasms that are frequently well-controlled with standard treatments that include surgical resection, radiotherapy, and agents that modulate hormonal excess. Unfortunately, a subset of patients remains uncontrolled or develops complications from these interventions. For these patients, chemotherapy is an additional treatment option that could improve outcomes. Temozolomide is an oral chemotherapy with a favorable side-effect profile that has shown activity against pituitary adenomas. Its non-overlapping toxicity and ability to induce rapid tumor regression renders it a potentially important adjunctive treatment. In patients with tumors that cannot be optimally addressed with standard treatments, there may be a role for early initiation of temozolomide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.